IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11566003 B1

PDFFull Text
Date of Patent:
Jan. 31, 2023

Filed:

Jul. 06, 2020

Isoquinolines as inhibitors of hpk1

Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Bryan Chan, Foster City, CA (US);

Joy Drobnick, Daly City, CA (US);

Lewis Gazzard, Belmont, CA (US);

Timothy Heffron, Burlingame, CA (US);

Jun Liang, Los Altos Hills, CA (US);

Sushant Malhotra, Burlingame, CA (US);

Rohan Mendonca, Pleasanton, CA (US);

Naomi Rajapaksa, San Mateo, CA (US);

Craig Stivala, San Mateo, CA (US);

John Tellis, San Mateo, CA (US);

Weiru Wang, Lafayette, CA (US);

BinQing Wei, Belmont, CA (US);

Aihe Zhou, San Jose, CA (US);

Matthew W. Cartwright, Harlow, GB;

Michael Lainchbury, Harlow, GB;

Emanuela Gancia, Harlow, GB;

Eileen Seward, Harlow, GB;

Andrew Madin, Harlow, GB;

David Favor, Shanghai, CN;

Kin Chiu Fong, Shanghai, CN;

Yonghan Hu, Shanghai, CN;

Andrew Good, Shanghai, CN;

Assignee:

Genentech, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:

Rei Tsang Shiao

Int. Cl.
CPC ...
C07D 217/22 (2006.01); A61K 31/549 (2006.01); A61P 35/00 (2006.01); A61K 45/06 (2006.01); C07D 401/04 (2006.01); A61K 31/4725 (2006.01); A61K 31/506 (2006.01); A61K 31/501 (2006.01); C07D 471/04 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); A61K 31/5377 (2006.01); C07D 417/04 (2006.01); A61K 31/4985 (2006.01); C07D 401/14 (2006.01); C07D 487/04 (2006.01); A61K 31/551 (2006.01); C07D 498/04 (2006.01); A61K 31/5383 (2006.01); C07D 405/14 (2006.01); C07D 519/00 (2006.01); C07D 498/14 (2006.01); C07D 513/04 (2006.01); A61K 31/554 (2006.01); A61K 31/55 (2006.01); A61K 31/472 (2006.01); C07D 409/14 (2006.01); C07D 491/04 (2006.01); C07D 487/14 (2006.01);
U.S. Cl.
CPC ...
C07D 217/22 (2013.01); A61K 31/472 (2013.01); A61K 31/4725 (2013.01); A61K 31/4985 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/549 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/554 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/14 (2013.01); C07D 491/04 (2013.01); C07D 498/04 (2013.01); C07D 498/14 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01);
Abstract

Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

Find Patent Forward Citations

Loading…